<DOC>
	<DOCNO>NCT02083016</DOCNO>
	<brief_summary>Ultra-high density mapping multielectrode catheter may improve slow conduction channel identification ventricular tachycardia substrate ablation procedure compare conventional point point mapping . This study compare ability map catheter detect slow conduction channel area myocardial scar utility ass substrate modification ablation .</brief_summary>
	<brief_title>Ultra-high Density Mapping With Multielectrode Catheter vs Conventional Point Point Mapping Ventricular Tachycardia Substrate Ablation</brief_title>
	<detailed_description>This prospective , randomize control study . Twenty patient sustain ventricular tachycardia structurally abnormal ventricle ( ) prospectively enrol . In patient detailed pre post-ablation electroanatomical mapping perform , map merge CT and/or MRI image . Patients randomly assign two group . In Group A patient pre post-ablation mapping perform firstly conventional point point map use Navistar Thermocool catheter , secondly multielectrode contact map use Pentaray catheter . In group , target ablation site guide point point map . In Group B patient , pre post-ablation mapping perform firstly multielectrode contact map use Pentaray catheter , secondly conventional point point map use Navistar Thermocool catheter . In group target ablation site guide multielectrode contact mapping . Slow conduction channel identify color-coded voltage map adjustment low upper threshold also presence fraction electrograms delay component show sequential orthodromic activation . The entrance channel target ablation site ( scar dechanneling technique ) .</detailed_description>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<criteria>Patients indication ventricular tachycardia substrate ablation . Pregnant woman . Reduced expectancy life ( le 12 month ) Patient participate another clinical study investigate drug device Psychologically unstable patient denies give informed consent Any cause contraindicate ablation procedure antiarrhythmic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>